In terms of regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed copy of newspaper advertisment published in English daily newspaper ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences has published its Q3 FY26 (quarter ended December 31, 2025) and nine-month financial results in newspapers as required by SEBI regulations. Consolidated total income from operations for Q3 FY26 stood at Rs. 4532.86 lacs, slightly lower than the Rs. 5536.53 lacs reported in the previous quarter (Q2 FY26), but massively higher than Rs. 151.08 lacs in Q3 FY25. For the nine-month period, consolidated revenue surged to Rs. 10965.06 lacs from Rs. 695.57 lacs in the same period last year. Net profit after tax for Q3 FY26 was Rs. 19.54 lacs (vs Rs. 4.27 lacs in Q3 FY25), while nine-month profit after tax rose to Rs. 84.52 lacs from Rs. 32.40 lacs. The company had reported a loss of Rs. 66.57 lacs for the full year FY25. EPS for nine months stood at Rs. 0.21 compared to a negative Rs. 0.17 for the full prior year. Results were approved by the Board on February 12, 2026.
The dramatic year-on-year revenue growth signals a major business expansion or new revenue stream coming online. The swing from a full-year loss in FY25 to a nine-month profit in FY26 is a positive turnaround signal for shareholders, though the sequential quarter-on-quarter dip from Q2 to Q3 is worth monitoring.